5-乙基-1-苯并噻吩 | 17514-96-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 5-乙基-1-苯并噻吩
• 英文名称: 5-ethylbenzothiophene
• 英文别名: 5-ethylbenzo[b]thiophene；5-Ethylbenzothiophen；5-ethyl-1-benzothiophene
• CAS: 17514-96-4
• 化学式: C₁₀H₁₀S
• 分子量: 162.255
• InChiKey: XXKJPQUVYBHFBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  n-butyllithium hexane 、 5-乙基-1-苯并噻吩 、 4-溴-2-萘甲醛 、 氯化铵 在 氮气 、 乙酸乙酯 、 氯化钠 、 magnesium sulfate 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 为溶剂， 反应 2.58h， 以to obtain the title compound (780 mg, 90%)的产率得到(4-Bromonaphthalen-2-yl)-(5-ethylbenzo-[b]thiophen-2-yl)methanol
  参考文献：
  名称：

  Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes

  摘要：

  本发明提供了一种葡萄糖醇衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，例如长效药物活性；以及用于预防或治疗由高血糖引起的疾病，例如糖尿病、糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：其中m是在1-3之间选择的整数；R1到R4各自独立地是可选的取代烷基等；Ar1是可选的取代萘基；A是可选的取代杂环基，该化合物的前药物或其药学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。

  公开号：

  US07943748B2
• 作为产物：
  描述：

  1-(2,2-Dimethoxyethylsulfanyl)-4-ethylbenzene 在 PPA 作用下， 以 氯苯 为溶剂， 以26%的产率得到5-乙基-1-苯并噻吩
  参考文献：
  名称：

  EP1803721

  摘要：

  公开号：

文献信息

• 6-Membered heterocyclic compound and use thereof
  申请人：Shoda Motoshi

  公开号：US20070060590A1

  公开（公告）日：2007-03-15

  A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH 2 and the like; R O1 to R O4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents —CH(OH)— group and the like; and W represent —U 1 —(R W1 )(R W2 )—U 2 —U 3 group (U 1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; R W1 and R W2 represent hydrogen atom and the like; U 2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U 3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoma, ulcerative colitis and the like.

  由通用公式(I)表示的化合物或其盐： [T代表氧原子等；V代表CH2等；RO1至RO4代表氢原子等；A代表具有2至8个碳原子的线型亚烷基或线型亚烯基等；D代表羧基等；X代表亚乙基、亚丙基等；E代表—CH(OH)—基团等；W代表—U1—(RW1)(RW2)—U2—U3基团（U1代表单键、具有1至4个碳原子的亚烷基等；RW1和RW2代表氢原子等；U2代表单键、具有1至4个碳原子的亚烷基等；U3代表具有1至8个碳原子的烷基等），或碳环或杂环化合物的残基]，其可作为预防性和/或治疗性药物的有效成分，用于治疗骨骼疾病如骨质疏松症和骨折、青光眼、溃疡性结肠炎等。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009062289A1

  公开（公告）日：2009-05-22

  Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

  公式I的化合物：其中c、R2、R3、R4、R5、R6、R7和R8按本说明定义，可用作HIV复制的抑制剂。
• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• Substituted bis-amide metalloprotease inhibitors
  申请人：Sucholeiki Irving

  公开号：US20070155739A1

  公开（公告）日：2007-07-05

  This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.

  这项发明涉及Formula (I)的取代双酰胺嘧啶化合物，这些化合物对于治疗金属蛋白酶介导的疾病，特别是MMP-13相关疾病是有用的。
• POLYMERIZABLE MONOMER, POLYMER COMPOUND FOR CONDUCTIVE POLYMER, AND METHOD FOR PRODUCING THE POLYMER COMPOUND
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20200247926A1

  公开（公告）日：2020-08-06

  Polymerization reaction is performed using a polymerizable monomer shown by the following general formula (1) and at least one monomer selected from monomers each having a structure of a salt among a lithium salt, a sodium salt, a potassium salt, and a nitrogen compound salt of a fluorosulfonic acid or the like; then, the structure of the salt of the repeating unit of a polymer obtained by the polymerization reaction is changed to the fluorosulfonic acid or the like by ion exchange. Thus, the present invention provides a polymer compound for a conductive polymer and a method for producing the polymer compound which is suitably used as a dopant for a fuel cell and a conductive material, and which is a copolymer containing a repeating unit of styrene having a 3,3,3-trifluoro-2-hydroxy-2-trifluoromethylisobutyl ether group, and a repeating unit having any of a fluorosulfonic acid, a fluorosulfonimide group, and a n-carbonyl-fluoro-sulfonamide group.

  聚合反应使用以下一般式（1）所示的可聚合单体和至少一种选择自锂盐、钠盐、钾盐和氟磺酸盐等盐结构的单体中的单体进行；然后，通过离子交换将聚合反应得到的聚合物的重复单元的盐结构改变为氟磺酸盐或类似物。因此，本发明提供了一种用作导电聚合物的聚合物化合物以及用作燃料电池和导电材料的掺杂剂的聚合物化合物的生产方法，该聚合物是含有3,3,3-三氟-2-羟基-2-三氟甲基异丁基醚基的苯乙烯重复单元和具有氟磺酸、氟磺酰亚胺基团和n-羰基-氟磺酰胺基团中的任何一种的重复单元的共聚物。